# Avalo Therapeutics Inc. (AVTX) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $7.25, market value $389 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Avalo Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 6590.1×**. Each dollar of revenue is priced at 6590.1×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 0.9×**. The shares trade below book value, which can signal a bargain or a balance sheet the market doubts.

## Profitability
- **Return on equity: -94.2%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -89.5%**. Return on all capital, debt included, is -89.5%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -67.2%**. Each dollar of assets produces -67.2% of profit.

## Growth
- **Revenue growth (1 yr): -86.6%** (3-yr -85.2%/yr, 5-yr -61.2%/yr). Revenue fell 86.6% over the last year, against -61.2% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 72.1%**. Earnings per share rose 72.1%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.17**. Debt is 0.17 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 0.0×**. It would take 0.0 years of operating earnings to repay net borrowings, within the comfortable range.
- **Current ratio: 8.14** (quick 8.14). Current assets cover the next year's liabilities 8.14 times.
- **Altman Z-score: 6.87**. A Z-score of 6.87 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Avalo Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (10 analysts). 10 analysts cover Avalo Therapeutics Inc.; the consensus is strong_buy, with an average price target of $36.60 (+405% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -59.4%** (YTD -59.7%, 3-mo -59.4%). The shares are down 59.4% over twelve months including dividends.
- **From 52-week high: -70.1%** (11.0% above the low). Trading 70% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 24**. An RSI of 24 is oversold; bounces are common, but oversold can stay oversold in a real decline.
- **Beta (1 yr): 1.50** (volatility 89%). Beta of 1.50 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=AVTX · Page: https://foliofundamentals.com/stocks/avtx

Not investment advice.